In the Margins
Hedge-fund billionaire John Paulson has joined the Valeant Pharmaceuticals International board of directors. Paulson has been one of the largest shareholders in the company for several years, but a series of scandals at Valeant over its accounting practices and drug pricing have battered the company’s stock and caused the value of Paulson’s stake to plunge 81% to $245 million at the end of last year from $1.3 billion in 2015. Read the original story from The Wall Street Journal.
Most Read
Fund industry litigators and others are watching an expansive class-action lawsuit filed recently against an interval fund that has been scheduled for liquidation since mid-2023, certain ...
Dimensional Fund Advisors is preparing to launch exchange-traded fund share classes of a selection of its open-end mutual funds in the early part of 2026, and ...
The very first independent chair we profiled for FBV was Leigh Wilson at Victory Funds, for our A Seat at the Table section. Victory Capital Management had recently redefined itself ...
The Securities and Exchange Commission's move earlier this week to greenlight Dimensional Fund Advisors' plan to offer ETF share classes of its mutual funds is likely ...